drugset / Trial / NCT06369363

Estrogen Deficiency on Cardiovascular Risk

NCT06369363

Phase 0 Not yet recruiting 20 enrolled Milton S. Hershey Medical Center
RandomizedParallel-groupTriple-blindBasic science

Summary

To explore how estrogen deficiency impacts the blood pressure (BP) and sympathetic nerve activity (SNA), and how it impacts the production of the key pro-inflammatory mediators such as Tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). It is hypothesized that estrogen deficiency increases BP, SNA and the pathway activities of the key pro-inflammatory mediators. Those effects are impacted through the downregulation of the estrogen receptor.

Timeline

Start
2026-09
Primary completion
2028-09
Completion
2028-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 0.05 mg Other